Samaritan Pharmaceuticals Inc., and Pharmaplaz LTD, a fully integrated healthcare company operating under cGMP with a manufacturing licence under EMEA, have entered into a broad strategic collaboration agreement for the production and supply of Samaritan's lead compound SP-01A.

The European Agency for the Evaluation of Medicinal Products (EMEA) is the European counterpart to the US Food and Drug Administration (FDA).

Under the terms of the alliance, Pharmaplaz will collaborate with Samaritan's SP-01A development, scale up, and manufacturing requirements, while working on drug formulation and testing, production of pilot batches, development of analytical methods, drug specifications, process validations and drug optimization. The companies will also work together to secure regulatory approval by the FDA for selected products in the U.S. markets.

Samaritan Pharmaceuticals, Ireland creates a virtual in-house facility; eliminating the hiring of contract manufacturers, savings could amount to as much as $500,000 per drug. Attractive tax breaks have turned Ireland into a major drug manufacturing center, with 13 of the top 15 drug makers now in Ireland.